These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

4654 related articles for article (PubMed ID: 35157371)

  • 1. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.
    Furie RA; Morand EF; Bruce IN; Manzi S; Kalunian KC; Vital EM; Lawrence Ford T; Gupta R; Hiepe F; Santiago M; Brohawn PZ; Berglind A; Tummala R;
    Lancet Rheumatol; 2019 Dec; 1(4):e208-e219. PubMed ID: 38229377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus.
    Furie R; Khamashta M; Merrill JT; Werth VP; Kalunian K; Brohawn P; Illei GG; Drappa J; Wang L; Yoo S;
    Arthritis Rheumatol; 2017 Feb; 69(2):376-386. PubMed ID: 28130918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trial of Anifrolumab in Active Systemic Lupus Erythematosus.
    Morand EF; Furie R; Tanaka Y; Bruce IN; Askanase AD; Richez C; Bae SC; Brohawn PZ; Pineda L; Berglind A; Tummala R;
    N Engl J Med; 2020 Jan; 382(3):211-221. PubMed ID: 31851795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study.
    Bruce IN; Nami A; Schwetje E; Pierson ME; Rouse T; Chia YL; Kuruvilla D; Abreu G; Tummala R; Lindholm C
    Lancet Rheumatol; 2021 Feb; 3(2):e101-e110. PubMed ID: 38279367
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials.
    Bruce IN; Furie RA; Morand EF; Manzi S; Tanaka Y; Kalunian KC; Merrill JT; Puzio P; Maho E; Kleoudis C; Albulescu M; Hultquist M; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):962-969. PubMed ID: 35580976
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials.
    Bruce IN; van Vollenhoven RF; Psachoulia K; Lindholm C; Maho E; Tummala R
    Lupus Sci Med; 2023 Jan; 10(1):. PubMed ID: 36639192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of RNase therapy in systemic lupus erythematosus: a randomised phase 2a clinical trial of RSLV-132.
    Burge DJ; Werth VP; Boackle SA; Posada J
    Lupus Sci Med; 2024 Feb; 11(1):. PubMed ID: 38325898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials.
    Morand EF; Furie RA; Bruce IN; Vital EM; Dall'Era M; Maho E; Pineda L; Tummala R
    Lancet Rheumatol; 2022 Apr; 4(4):e282-e292. PubMed ID: 38288923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab.
    Strand V; O'Quinn S; Furie RA; Morand EF; Kalunian KC; Schwetje EG; Abreu G; Tummala R
    Lancet Rheumatol; 2022 Mar; 4(3):e198-e207. PubMed ID: 38288936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus.
    Furie R; Morand EF; Askanase AD; Vital EM; Merrill JT; Kalyani RN; Abreu G; Pineda L; Tummala R
    Lupus; 2021 Jul; 30(8):1254-1263. PubMed ID: 33977796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials.
    Vital EM; Merrill JT; Morand EF; Furie RA; Bruce IN; Tanaka Y; Manzi S; Kalunian KC; Kalyani RN; Streicher K; Abreu G; Tummala R
    Ann Rheum Dis; 2022 Jul; 81(7):951-961. PubMed ID: 35338035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
    Chia YL; Zhang J; Tummala R; Rouse T; Furie RA; Morand EF
    Rheumatology (Oxford); 2022 May; 61(5):1900-1910. PubMed ID: 34528084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
    Furie R; Morand EF; Bruce IN; Isenberg D; van Vollenhoven R; Abreu G; Pineda L; Tummala R
    Arthritis Rheumatol; 2021 Nov; 73(11):2059-2068. PubMed ID: 33913260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus.
    Morand EF; Abreu G; Furie RA; Golder V; Tummala R
    Ann Rheum Dis; 2023 May; 82(5):639-645. PubMed ID: 36690388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
    Morand E; Pike M; Merrill JT; van Vollenhoven R; Werth VP; Hobar C; Delev N; Shah V; Sharkey B; Wegman T; Catlett I; Banerjee S; Singhal S
    Arthritis Rheumatol; 2023 Feb; 75(2):242-252. PubMed ID: 36369798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient-Reported Outcomes from a Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Repository Corticotropin Injection (Acthar
    Askanase AD; Wan GJ; Panaccio MP; Zhao E; Zhu J; Bilyk R; Furie RA
    Rheumatol Ther; 2021 Mar; 8(1):573-584. PubMed ID: 33687687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M; Merrill JT; Werth VP; Furie R; Kalunian K; Illei GG; Drappa J; Wang L; Greth W;
    Ann Rheum Dis; 2016 Nov; 75(11):1909-1916. PubMed ID: 27009916
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
    Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 233.